{"filings":[{"id":99527,"accession_number":"0001193125-26-212117","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Pediatrix shareholders approve 8M share increase in incentive plan; director Starcher faces 36% withhold vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved the Second Amended and Restated 2008 Incentive Compensation Plan, increasing authorized shares by 8,000,000.","Director John M. Starcher, Jr. received 46,296,745 votes for (55%) and 25,909,618 against (36% of votes cast excluding broker non-votes).","PricewaterhouseCoopers LLP ratified as auditor for 2026 with 75,519,473 for (97.6% of votes cast).","Advisory vote on named executive officer compensation for 2025 approved with 70,257,832 for (97.3% of votes cast excluding broker non-votes).","All other director nominees received over 98% support from votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99526,"accession_number":"0001193125-26-204982","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q1 GAAP EPS $0.36, Adj. EPS $0.44; revenue $476M, beat expectations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $476.2M, up 4% YoY from $458.4M; same-unit revenue grew 2.8%.","Adjusted EBITDA $58.2M vs $49.2M YoY; net income $29.6M ($0.36 diluted) vs $20.7M ($0.24).","Same-unit volume down 1.6% (hospital services -1.5%, office -3.3%) but reimbursement up 4.4%.","Reaffirmed FY2026 Adjusted EBITDA guidance range of $280M-$300M.","Used $21.5M for share repurchases and $7.0M for acquisitions in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":476196000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115581,"accession_number":"0001193125-26-058063","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q4 EPS $0.40; Adj. EPS $0.50; guides 2026 EBITDA $280-300M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $494M, down slightly YoY; same-unit revenue up 4.0%.","Q4 GAAP net income $33.7M ($0.40/share) vs $30.5M ($0.36) prior year; Adjusted EPS $0.50.","Full year 2025 Adjusted EBITDA $275.6M, up from $224M; Adjusted EPS $2.04 vs $1.51.","Preliminary 2026 Adjusted EBITDA guidance $280-300M, above 2025's $275.6M.","Cash from operations $114.6M in Q4; used $64M for share repurchases; total debt $597M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":1913849000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132006,"accession_number":"0001193125-25-261626","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q3 EPS $0.84, revenue $493M; raises FY2025 Adj. EBITDA outlook to $270-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $71.7M ($0.84/share) vs $19.4M ($0.23) year ago; adjusted EPS $0.67 vs $0.44.","Net revenue $492.9M, down 3.6% YoY; same-unit net revenue rose 8.0%.","Adjusted EBITDA $87.3M vs $60.2M; guidance raised to $270-290M from prior range.","Same-unit volume growth of 0.4%; NICU days up 2.2% and reimbursement factors up 7.6%.","Used $20.9M for share repurchases, $19.2M for acquisitions in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":1420078000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148584,"accession_number":"0000950170-25-109777","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pediatrix Medical Group announces $250M share repurchase program with three-year term","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $250M in share repurchases of outstanding common stock over three years.","CEO Mark Ordan cites strong cash flow, current cash balances, and low debt levels as rationale.","Repurchases may be made via open market or privately negotiated transactions, including 10b5-1 plans.","Program may be suspended or discontinued at any time; no obligation to repurchase any specific amount.","Company will weigh repurchases against other strategic uses of cash for long-term shareholder returns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148583,"accession_number":"0000950170-25-102375","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q2 EPS $0.46, Adjusted $0.53; raises FY 2025 EBITDA guidance to $245-255M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $469M; net income $39M vs. loss of $153M a year ago due to non-cash impairment.","Adjusted EBITDA $73M, up from $58M in Q2 2024; raised FY guidance to $245-255M (from $220-240M).","Same-unit revenue +6.4% with neonatology NICU days up 6.0% year-over-year.","Cash from continuing operations $138M; total debt $606M; no revolver borrowings."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":927203000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148582,"accession_number":"0000950170-25-092261","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pediatrix appoints Dr. Kurt Newman as independent director effective July 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Newman, former President & CEO of Children's National Hospital for 12 years, appointed to board.","He is a pediatric surgeon and professor emeritus, bringing clinical insight and healthcare leadership.","Receives standard non-employee director compensation; enters indemnification agreement with company.","No arrangements with other persons regarding his appointment; no committee assignments yet determined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167434,"accession_number":"0000950170-25-067076","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pediatrix shareholders elect all 8 director nominees, ratify PwC, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 management director nominees elected with 70M+ votes each; broker non-votes of ~5.5M.","PricewaterhouseCoopers ratified as auditor for FY2025: 76.5M for, 1.3M against.","Non-binding say-on-pay proposal approved: 67.1M for, 4.95M against, 333K abstain.","Meeting held May 8, 2025; ~77.9M of 85.8M outstanding shares represented (quorum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167433,"accession_number":"0000950170-25-063946","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q1 adjusted EPS $0.33; raises FY2025 EBITDA guidance to $220-240M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $458M, down 7% YoY due to dispositions; same-unit revenue grew 6.2% on improved payor mix and volume.","Adjusted EBITDA $49.2M (up 32% YoY); GAAP EPS $0.24 vs $0.05; Adjusted EPS $0.33 vs $0.20.","Raised FY2025 Adjusted EBITDA guidance to $220-240M from $215-235M after strong Q1.","Cash from ops used $116.1M for seasonal incentive comp; total debt $611M, no revolver draw.","Same-unit volume: NICU days +2.0%, hospital-based +1.7%, office-based +2.6% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":458359000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167432,"accession_number":"0000950170-25-055880","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Pediatrix extends Guidehouse services pact to June 30, 2025; adds SOW #2 from July 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PMG Services and Guidehouse amended SOW #1 to extend term from April 19, 2025 through June 30, 2025.","New SOW #2 starts July 1, 2025, with Guidehouse providing services for fixed, variable, and incentive payments.","Incentive payments tied to Guidehouse achieving certain performance metrics under SOW #2.","Agreement originally dated April 19, 2024, between PMG Services (Pediatrix subsidiary) and Guidehouse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184732,"accession_number":"0000950170-25-023723","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q4 net income $30M, Adjusted EPS $0.51, revenue up to $502M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.36 (vs $1.50 loss Q4 2023); Adjusted EPS $0.51 (vs $0.32).","Net revenue $502M, up from $496M; same-unit revenue grew 8.7%.","Adjusted EBITDA $68.7M (vs $50.8M); portfolio restructuring completed by Dec 31, 2024.","Preliminary 2025 Adjusted EBITDA guidance $215M-$235M.","Cash from operations $134.8M; total debt $616M; no revolver borrowings."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":2012919000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184731,"accession_number":"0001193125-25-006190","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mark S. Ordan appointed CEO of Pediatrix Medical Group effective Jan 12, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Ordan, 65, appointed CEO; he was CEO from 2020-2022 and most recently Executive Chair, succeeding Dr. Swift.","Employment agreement: $1M base salary, $2M one-time cash retention award, annual bonus target 150% of salary.","Equity transformation award: 640,000 performance share units with stock price hurdles of 125%, 150%, and 175%.","Annual equity grants of at least $5.5M; severance for cause-less termination: 2x base+bonus, 3x under change in control.","Dr. Swift's departure is termination without cause; he will receive severance benefits under prior employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184730,"accession_number":"0001193125-25-004937","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pediatrix appoints Mark Ordan as CEO, expects 2024 adjusted EBITDA to exceed $215M guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark S. Ordan returns as CEO effective immediately, succeeding James D. Swift who will assist transition.","2024 adjusted EBITDA expected at high end of $205M-$215M range or possibly above; results due Feb 20.","Company refocusing on hospital relationships, divesting primary/urgent care clinics, and restructuring leadership.","Ordan led Pediatrix restructuring as CEO from 2020-2022 and has turnaround experience at Sunrise, ManorCare.","Board cites need to accelerate strategy for shareholder value; Ordan served as Executive Chair since Oct 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201311,"accession_number":"0000950170-24-133723","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pediatrix Medical Group announces departure of EVP & Chief Physician Executive Curtis Pickert effective Jan 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Curtis B. Pickert will transition from his roles as EVP, Chief Physician Executive and former COO effective January 31, 2025.","Pickert was notified on November 29, 2024; his departure is a termination without Cause under his employment agreement.","He will receive contractual benefits after executing a general release of claims in favor of the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201310,"accession_number":"0000950170-24-119795","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Q3 adjusted EPS $0.44, revenue $511M; reaffirms FY 2024 EBITDA guidance $205-215M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $511M, up from $506.6M YoY; same-unit revenue grew 5.2% (reimbursement +3.4%, volume +1.8%).","GAAP EPS $0.23, down from $0.26 YoY; Adjusted EPS $0.44 vs $0.32; Adjusted EBITDA $60M vs $50.4M.","Exiting almost all office-based practices (except maternal-fetal medicine); expects ~$30M annualized EBITDA benefit by year-end.","Cash from operations $95.7M; total debt $619M, no revolver borrowings; completed hybrid RCM transition.","FY 2024 Adjusted EBITDA guidance $205-215M, implying Q4 roughly $50-60M based on YTD result of $155.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1510555000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217343,"accession_number":"0000950170-24-091185","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Pediatrix Medical Group Q2 net loss $153M (-$1.84/share); Adjusted EPS $0.34 vs $0.39; CFO transition planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $153M ($1.84 loss per share) vs net income $28.3M ($0.34 EPS) in Q2 2023, driven by $192.9M impairment.","Adjusted EPS fell to $0.34 from $0.39; Adjusted EBITDA $57.9M vs $59.1M. Revenue $504.3M (+0.7% YoY).","Company exits office-based and primary/urgent care practices; expects ~$30M annualized EBITDA benefit; guidance reaffirmed $200-220M.","CFO transition: Kasandra Rossi appointed to succeed Marc Richards effective ~Oct 1, 2024.","Mary Ann Moore appointed CAO; Dr. Curtis Pickert transitions from COO to Chief Physician Executive (no longer exec officer)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":999397000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237165,"accession_number":"0000950170-24-074283","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pediatrix eliminates EVP role of Lee Wood; departure by July 5, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lee A. Wood's role as EVP of National and Market Operations eliminated effective July 5, 2024.","Termination is without cause under second amended employment agreement dated April 2023.","Departure part of company's previously announced continued focus on operating efficiency.","No replacement named; the role is eliminated as part of restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237164,"accession_number":"0000950170-24-066242","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pediatrix Medical Group reiterates 2024 Adj. EBITDA guidance of $200M-$220M, portfolio optimization with $30M impact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company exiting office-based practices and primary/urgent care by end of 2024.","Annualized Adj. EBITDA impact of portfolio optimization ~$30M (based on 2023 results).","Reiterates 2024 Adj. EBITDA guidance range of $200M to $220M, including in-year impact.","Focus on operating efficiency and margin stabilization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237163,"accession_number":"0000950170-24-057093","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pediatrix shareholders elect all 9 director nominees, ratify PwC, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; votes for ranged from 72.6M to 74.1M, against 0.9M-2.3M.","Ratification of PricewaterhouseCoopers as auditor for 2024: 75.2M for, 2.4M against.","Advisory vote on 2023 executive compensation approved: 71.7M for, 3.3M against, 2.6M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237162,"accession_number":"0000950170-24-053917","cik":893949,"company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pediatrix Medical Q1 GAAP EPS $0.05 vs $0.17 YoY; revenue up slightly to $495M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $495M vs $491M YoY; same-unit revenue up 2.3%.","Net income $4M down from $14.2M; GAAP EPS $0.05 vs $0.17.","Adjusted EPS $0.20 vs $0.23; Adjusted EBITDA $37M vs $40.1M.","FY 2024 Adjusted EBITDA guidance reaffirmed $200M-$220M.","Cash used in ops $122.6M; total debt $705M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":495101000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1777939474.4109464,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}